Announced
Completed
Financials
Tags
enzyme-based products
treatment development
Biotechnology
Acquisition
Majority
Friendly
United States
Private
Private Equity
Completed
Domestic
Single Bidder
Synopsis
Linden Capital Partners, a Chicago-based private equity firm, completed the acquisition of Alcresta Therapeutics, a provider of novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Financial terms were not disclosed. "I am very excited to join the Alcresta team to support the continuing growth of the company. Alcresta's rapid progress has made a meaningful difference for patients living with rare diseases that struggle with fat malabsorption. Linden feels very fortunate to partner with Alcresta as it prepares for new levels of momentum and success in the years ahead," Ron Labrum, Linden Operating Partner.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.